Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Nov 9 - Nov 14
Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Reasons for treatment discontinuation include, but are not limited to, gastrointestinal adverse effects, less-than-desired efficacy, high cost, and fear about uncommon or rare adverse effects
Fresh fruits, vegetables, salads, and lean proteins provide more nutrients and are more satisfying than a shake, bar, or processed snack
If more employers exclude weight-loss GLP-1s, patients may shift toward cash-pay programs, lower-dose options, oral drugs or cheaper clinical models
US$ 27.89
US$ 23.73
US$ 29.18
US$ 24.20
US$ 20.61
US$ 23.21
US$ 27.18
US$ 25.28
